Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.

14 Within 12 months, this study reported higher MACE risk in the antagonist group (5.5%) compared to the agonist group (4.1%); however, the difference in risk favoring agonists did not reach statistical significance (HR=1.28; 95% CI 0.59-2.79, P = .53) as the study was stopped prematurely (545 patients enrolled out of 900 patients planned). 14 Thus, there is insufficient evidence to definitively determine whether risk of CV events varies by drug class.

also in 111,027 other papers